Form 4: Arbutus Biopharma CFO Sells Shares to Cover Tax Obligations
SEC Form 4
David C. Hastings, CFO of Arbutus Biopharma, sold shares to cover tax obligations related to vesting restricted stock units.
Summary
- On February 4, 2025, David C. Hastings, the Chief Financial Officer of Arbutus Biopharma Corp, sold 22,183 common shares.
- The sale was executed at a price of $3.283 per share.
- This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on March 6, 2023.
- The purpose of the sale was to satisfy tax obligations related to the vesting of previous grants of restricted stock units.
- Following the transaction, Hastings directly owns 159,724 common shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice.
Positives
- The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was planned and not based on immediate market conditions.
Industry Context
Sales of shares by company executives are a normal part of corporate governance. Often these sales are pre-planned to avoid any accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023/03/06 | Date of adoption of the 10b5-1 trading plan. |
| 2025/02/04 | Date of the share sale transaction. |
| 2025/02/05 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.